TRDA - Entrada Therapeutics Inc

TRDA - Entrada Therapeutics Inc

https://www.entradatx.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Entrada Therapeutics ( NASDAQ:TRDA )

Benzinga • 1 week, 5 days ago • score: 0.24

BOSTON, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. ( TRDA ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - Entrada Therapeutics ( NASDAQ:TRDA ) , Biogen ( NASDAQ:BIIB )

Benzinga • 3 months, 1 week ago • score: 0.30

BOSTON, June 03, 2025 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Entrada Therapeutics ( NASDAQ:TRDA )

Benzinga • 3 months, 1 week ago • score: 0.26

BOSTON, June 02, 2025 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA today announced that the Company granted an aggregate of 23,820 restricted stock units ( "RSUs" ) to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan ( the "Inducement Plan" ) , ...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 3 months, 1 week ago • score: 0.27

Entrada Therapeutics announces inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

Entrada Therapeutics, Inc. ( TRDA ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: 0.02

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 46.15% and 111.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

None

52W High

$21.79

52W Low

$4.93

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.13

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

3333.33

EV/EBITDA (<8 favorable)

1.58

EV/Revenue (<3 favorable)

0.64

P/S (TTM) (<3 favorable)

2.53

P/B (<3 favorable)

0.53

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

12.30%

Institutions (25–75% balanced)

78.12%

Shares Outstanding

38,037,100

Float

19,081,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

79,476,000

Gross Profit (TTM)

-55,138,000

EPS (TTM)

-2.03

Profit Margin (>10% good)

-0.92%

Operating Margin (TTM) (higher better)

-24.03%

ROE (TTM) (>15% strong)

-0.18%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.98

Momentum

Bearish momentum

Value

-0.2040

Previous

-0.2142

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025